Covid-19 and Diabetes in West of Algeria

• Conditions: Coronavirus Infections; Diabetes Mellitus; Prevalence; Risk Factors; Patient Outcome Assessment; Severe Acute Respiratory Syndrome

• Registration Number: NCT04412746
• Lead Sponsor: Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen

Brief Summary

By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China.

It is known that some predisposing conditions lead to a worse outcome with coronavirus.

In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36).

The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms.

In the future, this study will provide answers for two main questions

1. Why diabetics are more at risk of developing Covid-19 infection?

2. Why diabetics are at high risk of developing severe forms?

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-01
• Status Verified: 2020-06
• Study First Submitted: 2020-06-01
• Study First Submitted QC: 2020-06-01
• Last Update Submitted: 2020-06-01
• Study First Posted: 2020-06-02
• Last Update Posted: 2020-06-02
• Primary Completion: 2020-06-30
• Study Completion: 2020-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients admitted in a hospital center since 1th April 2020
• Patients with COVID19 with biological proof (specific PCR) or with clinical and radiological diagnosis.
• Patient with diabetes known before the admission
• New onset diabetes discovered at admission (plasma glycaemia value strictly greater than 2 g/l at any time)

Exclusion Criteria

• Pregnant
• Active Cancer
• Dementia
• Minors, adults under guardianship, protected persons
• Significant disability (The Modified Rankin Scale more than 2 prior admission)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of diabetes among all hospitalized COVID-19	3 months	Assess the prevalence of diabetes among hospitalized patients with Covid-19 in Area of Tlemcen
Diabetes-related factors risk	3 months	Describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19

Trial Locations

Locations (1)

Department of Internal Medicine, Acedemic Hospital of Tlemcen; 🇩🇿 Tlemcen, Algeria